CN1309409C - Chinese medicine composite for treatment and prevention of cerebral arteries obstruction - Google Patents
Chinese medicine composite for treatment and prevention of cerebral arteries obstruction Download PDFInfo
- Publication number
- CN1309409C CN1309409C CNB011367709A CN01136770A CN1309409C CN 1309409 C CN1309409 C CN 1309409C CN B011367709 A CNB011367709 A CN B011367709A CN 01136770 A CN01136770 A CN 01136770A CN 1309409 C CN1309409 C CN 1309409C
- Authority
- CN
- China
- Prior art keywords
- radix
- kinds
- chinese crude
- chinese medicine
- crude drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to Chinese medicinal composition which has the efficacy of inhibiting platelet aggregation and prolonging the coagulation time, and can be used for treating and preventing cerebral artery blockage. The Chinese medicinal composition of the present invention comprises at least 6 kinds of the following 8 Chinese medicinal plants: ginseng, Chinese angelica, astragalus root, licorice root, bupleurum root, coptis root, tabasheer and baikal skullcap root.
Description
Invention field
The invention relates to the Chinese medicine medical component, the effect that it has anti-platelet aggregation and prolongs clotting time, and can be used for treatment and prevention of brain obstruction of artery.
Background technology
Though the pharmacologically active to some prescriptions of Chinese medicine statement so far has anti-platelet aggregation and prolongs clotting time does not have a kind of prescriptions of Chinese medicine to have significant curative effect on the treatment cerebral arteries emphraxis.
Summary of the invention
One of the object of the invention is to propose a kind of Chinese medicine medical component.
Another purpose of the present invention proposes a kind of active Chinese medicine medical component of anti-platelet aggregation that has.
Another purpose of the present invention is to propose a kind of active Chinese medicine medical component of the clotting time of prolongation that has.
Another purpose of the present invention is to propose a kind of being used for the treatment of and the Chinese medicine medical component of prevention of brain obstruction of artery.
Another purpose of the present invention also discloses simultaneously a kind ofly to be used Chinese crude drug to prepare to be used for the treatment of and the method for the medicine of prevention of brain obstruction of artery.
Foundation a kind of Chinese medicine medical component of the present invention comprises at least six kinds in following eight kinds of Chinese crude drugs: Radix Ginseng, Radix Angelicae Sinensis, the Radix Astragali, Radix Glycyrrhizae, Radix Bupleuri, Rhizoma Coptidis, Concretio silicea Bambusae seu schizostachyi and Radix Scutellariae.Preferable, it comprises in these eight kinds of Chinese crude drugs seven kinds.Better, it comprises this eight kinds of Chinese crude drugs.When this Chinese medicine medical component comprised in these eight kinds of Chinese crude drugs six kinds, not involved two kinds was Radix Bupleuri and Rhizoma Coptidis.If only comprise seven kinds, then not involved is Rhizoma Coptidis.
The present invention also discloses simultaneously and a kind ofly uses aforementioned Chinese medicine medical component of the present invention to prepare to be used for the treatment of and the method for the medicine of prevention of brain obstruction of artery.
Be determined pharmacologically active according to the prepared Chinese medicine medical component of a preferred embodiment of the present invention, and prolong the pharmacologically active of clotting time with anti-platelet aggregation.This Chinese medicine medical component also has curative effect through the zoopery proof to treatment and prevention of brain obstruction of artery, and the data of safety pharmacological testing and subacute toxicity test (28 days) also show the misgivings of its no safety.
Preferable, these eight kinds of Chinese crude drugs are exsiccant powder.These eight kinds of Chinese crude drugs can be obtained from general Chinese medicine is capable, obtain the back by further infusion, cure, dry and grind and promptly become exsiccant powder.
The weight ratio of eight kinds of Chinese crude drugs in the Chinese medicine medical component of the present invention, preferable, be Radix Ginseng: Radix Angelicae Sinensis: the Radix Astragali: Radix Glycyrrhizae: Radix Bupleuri: Rhizoma Coptidis: Concretio silicea Bambusae seu schizostachyi: Radix Scutellariae=140 ± 10%: 166 ± 10%: 180 ± 10%: 67 ± 10%: 140 ± 10%: 120 ± 10%: 120 ± 10%: 67 ± 10%, wherein when this medical component comprises six in these eight kinds of Chinese crude drugs or seven kind, the consumption that is not contained in one in this medical component or two kind is zero.
Being applicable to that Radix Ginseng of the present invention (Ginseng radix) includes, but is not limited to Fructus Arctii (Panax ginseng C.A.Meyer) and Radix Panacis Quinquefolii (Panax quinquefoliumLinnaeus), is preferable with the former.The Radix Ginseng capable from Chinese medicine or the trader obtains steams with food steamer in advance, cooperates the ratio of 1 kilogram of rice wine with 3 jin of water purification, and big fire is rolled the back low baking temperature and steamed about 1 hour 30 minutes, treats coldly, dries the back section.Put into dehydrator then,, pulverize again with 50 degree temperature continuous oven drying 13 hours.1000 g of Japan remain 930 g after participating in oven dry approximately.
Be applicable to that Radix Angelicae Sinensis of the present invention (Angelica sinensis radix) is the root of Angelicasinensis (Oliv.) Diels, or not section Radix Angelicae Sinensis that trader obtain capable from Chinese medicine, the quick hydro-peening of going ahead of the rest, limpid up to water breakthrough, wash down with distilled water again.20 kilograms of Radix Angelicae Sinensis are put into food steamer.Pour R.O. reverse osmosis water and 1 kilogram and 100 g Rhizoma Cyperis of rice wine head of 3 kilograms in the pot into.Change little fire with big fire boiling back, the constantly boiling shape reaches one hour, takes out the section after cooling that intersperses.The Radix Angelicae Sinensis of slabbing is put into automatic drier again, with 55 degree bakings Celsius 10 hours, pulverizes again.1000 g Radix Angelicae Sinensis remains 600 g approximately after oven dry.Levisticum officinale Koch and Angelica archangelica should be regarded as the substitute of Radix Angelicae Sinensis according to the instruction of United States Patent (USP) 4843067.
Be applicable to that the Radix Astragali of the present invention (Astragali radix) includes, but is not limited to Radix Astragali (Astragalus membranaceus (Fisch.) Bunge var.membranaceus), the root of Radix Astagali (Astragalus membranaceus (Fisch.) Bunge var.mongholicus (Bunge) Hsiao) and Hedysarum polybotrys Hand.-Mazz. (Hedysarum polybotrysHand.-Mazz.).Or the Radix Astragali that trader obtain capable from Chinese medicine cleaned back section shape, inserts dehydrator, with 50 degree temperature continuous oven drying 16 hours, pulverizes again.1000 g the Radix Astragali remains 650 g approximately after oven dry.
Be applicable to that Radix Glycyrrhizae of the present invention is Glycyrrhiza uralensis Fisch., Glycyrrhiza glabra L. or Glycyrrhiza inflata Bat. rhizome are preferable with Glycyrrhiza uralensis Fisch..Radix Glycyrrhizae capable from Chinese medicine or that the trader obtains is cleaned the back section, with 50 degree oven dry 12 hours, pulverizes again.1000 g Radix Glycyrrhizae remains 720 g approximately after oven dry.
Be applicable to that Radix Bupleuri of the present invention (Bupleurum radix) is HERBA BUPLEURI (Radix Bupleuri) (Bupleurm chinensis DC), Radix Bupeuri Scorzonerfolii. (Radix Bupleuri Scorzonerifolii) (Bupleurmscorzonerifolium Willd.) and other belong to the root of kindred plant together, are preferable with HERBA BUPLEURI (Radix Bupleuri).Radix Bupleuri capable from Chinese medicine or that the trader obtains is cleaned, is dried after 12 hours, pulverizes again.1000 g Radix Bupleuri remains 710 g approximately after oven dry.
Be applicable to that Rhizoma Coptidis of the present invention is Coptis teeta (Coptis chinensis Franch.), Coptis deltoidea C.Y.Cheng et Hsiao (Coptis deltoidea C.Y.Cheng et Hsiao), Coptis Teeta Wall (Coptisteetoides C.Y.Cheng) and other belong to the kindred plant rhizome together.Rhizoma Coptidis capable from Chinese medicine or that the trader obtains is cleaned the back with 50 degree oven dry 12 hours, pulverizes again.1000 g Rhizoma Coptidis remains 750 g approximately after oven dry.
Be applicable to that Concretio silicea Bambusae seu schizostachyi of the present invention (Bambusae concretio silicea) is grass phyllostachys nigra (lodd.ex lindl.) munro var.henonis (miff.) spapf et rendle (Phylllostachys nigra MUNRO var.henonis STAPF exRENDLE) and belongs to kindred plant together, due to illness generates block in joint.Concretio silicea Bambusae seu schizostachyi capable from Chinese medicine or that the trader obtains is cleaned earlier, and it is then good to swim., pulverize again after 18 hours with 55 degree continuous oven drying.1000 g Concretio silicea Bambusae seu schizostachyi remains 850 g approximately after oven dry.
Be applicable to that Radix Scutellariae of the present invention (Scutellariae radix) is the root of Scutellariabaicalensis Georgi.After Radix Scutellariae capable from Chinese medicine or that the trader obtains is cleaned, 10 kilograms of Radix Scutellariaes are put into food steamer, pour 100 g of 3 kilograms in R.O. reverse osmosis water and Fructus Corni in the pot into, change little fire with big fire boiling back, the constantly boiling shape reaches one hour.Take out and place the section of cooling back.Putting into automatic drier afterwards, pulverizes after 11 hours with 50 degree bakings again.1000 g Radix Scutellariae remains 700 g approximately after oven dry.
The specific embodiment
Fructus Arctii, Radix Angelicae Sinensis, the Radix Astragali, Radix Glycyrrhizae, Radix Bupleuri, Rhizoma Coptidis, Concretio silicea Bambusae seu schizostachyi and the Radix Scutellariae Chinese crude drug buied from the trader, and the Fructus Arctii of buying through identification of origin respectively be Panaxginseng C.A.Meyer, when be classified as Angelica sinensis (Oliv.) Diels, the Radix Astragali is that Hedysarum polybotrys Hand.-Mazz., Radix Glycyrrhizae are that Glycyrrhizauralensis Fisch., Radix Bupleuri are that Bupleurum longesadiatum Turca., Rhizoma Coptidis are that Coptis chinensis Franch., Concretio silicea Bambusae seu schizostachyi are Bambusa textilisMcCluture; Schizostachyum chinense Rendle and Radix Scutellariae are Scutellariabaicalensis Georgi.According to preceding method these eight kinds of Chinese crude drugs are added give infusion, cure, dry and grind the powder that becomes by mesh 10.
According to Radix Ginseng: Radix Angelicae Sinensis: the Radix Astragali: Radix Glycyrrhizae: Radix Bupleuri: Rhizoma Coptidis: Concretio silicea Bambusae seu schizostachyi: Radix Scutellariae=140: 166: 180: 67: 140: 120: 120: 67 part by weight is mixed into a Powdered medical component, and called after BNG-1.
Embodiment 1:
1. test substances and dosage profile are composed
BNG-1 is dissolved in the distilled water.In animal experiment, giving the mice oral dose is 20 milliliters/kilogram (PO).The predose that tested animal is accepted is 1000 milligrams/kilogram of every days, continuous 8 days.In test tube was analyzed, before the agonistic muscle effect of assessment or the platelet aggregation of challenge arachidonic acid, 0.1 milliliter substances was added in 10 milliliters of isolating tissue baths co-cultivation 5 minutes, and its ultimate density is 1000 mcg/ml.
2. animal
In these researchs, male/female ICR mice, and New Zealand male/female albinism rabbit is that animal feeding center by MDS general ball institute of pharmacology Taiwan company is provided.All animals all maintained at least one week in the laboratory in Taiwan, MDS general ball institute of pharmacology earlier before experiment, its condition is control temperature (22 ℃-24 ℃) and humidity (60%-80%), and per 12 hours circulation lights and dark are once.
3. method:
Arachidonic acid, the male or female albinism rabbit of New Zealand that the agonistic muscle effect of platelet aggregation/anti-agonistic muscle effect (Arachidonic Acid, Platelet Aggregation Agonism/Antagonism) venous blood is taken from body weight 2.5-3 kilogram.After blood sample mixes the trisodium citrate (0.13M) of 1/10th volumes, room temperature centrifugal 10 minutes with 220g.0.025 the test substances of milliliter is added in 0.45 milliliter the tissue bath, making test concentrations is 1000 mg/ml.Measure with the agglutination test device, in 5 minutes, contain the hematoblastic blood plasma (6 * 10 of a large amount
8Platelet/milliliter), in 37 ℃ control response, has 50% or the cohesion of more (〉=50%), demonstrate arachidonic acid acceptor agonistic muscle activity with respect to the long-pending molar concentration arachidonic acid of matched group 100 microbodys.Observe by one group of concentration of not having an active substances of agonistic muscle, can reduce the maximum non-reversible coagulation that brings out by arachidonic acid and react 50% or more (〉=50%), demonstrate the arachidonic acid acceptor and pick anti-flesh activity.Each concentration is all with twice sample test of preparation respectively.
Bleeding time (PO)
The male ICR mouse of one group of 5 body weight, 22 ± 2 gram, control PO every day, 1000 milligrams of/kilogram dosage were totally seven days; After giving hour of oral 1000 milligrams of/kilogram dosage on the 8th day, carry out the most advanced and sophisticated standard transversal (0.5 millimeter) of afterbody.Immediately 2 centimeters of mouse tail tail ends in the holder are vertically immersed and be equipped with in saline solution, 37 ℃ the test tube.Record takes to stopping to bleed by bleeding and surpasses 15 seconds time data, is the maximum of time set with 180 seconds.Bleeding time is than the significance that is considered to have of the prolongation 50% of control group or more (〉=50%).
4. result:
| AA-platelet Agg-antag a) | External | 1000μg/ml | 100％ | n＝2 |
| AA-platelet Agg-antag a) | External | 300μg/ml | 100％ | N＝2 |
| AA-platelet Agg-antag a) | External | 100μg/ml | 0％ | N＝2 |
| Bleeding time | Oral | 1000mg/kg×8 | 60％ | N＝5 |
| Bleeding time | Oral | 1000mg/kg×8 | 63％ | Repeat n=5 |
| Bleeding time | Oral | 300mg/kg×8 | 0％ | N＝5 |
A)Arachidonic acid, the agonistic muscle effect of platelet aggregation/anti-agonistic muscle effect
Embodiment 2:
1. test substances and dosage profile are composed
The 1st group (5 white mice): vehicle control
At MCAO and after first day, give 10 milliliters/kilogram saline solution oral (PO), after this gave oral in continuous 7 days every 24 hours.
The 2nd group (5 white mice): positive reaction control (MK-801)
After MCAO 0,6,24,30,48 and 54 hours, MK-801 is made into 5 milliliters/kilogram, carry out peritoneal injection with 0.3 milligram/kilogram dosage.
The 3rd group of (5 white mice): BNG-1 handles
BNG-1 is dissolved in the saline solution, is made into 10 milliliters/kilogram, with 1000 milligrams/kilogram dosage, behind first day MCAO and gave oral (PO) thereafter every 24 hours, continuous 7 days.
2. animal
180-240 g of (10 age in week) male Sprauge Dawely white mice provided by Univ Nat Taiwan's medical college animal center.Animal all maintains earlier in the laboratory in Taiwan, MDS general ball institute of pharmacology before experiment, at least one week, its controlled condition is temperature (22 ℃-24 ℃) and humidity (60%-80%), and per 12 hours circulation lights and dark once () at 6 o'clock in 6 o'clock/afternoon in the morning
3. equipment
Borer (the UPOWER UG 33 of tooth section, SELECTOR-M), image analyzers (LifeScience Resources VISTA Version 3.0), infant incubator (BrightenLife BL-90-SC) amplifies stereoscopic microscope (ZEISS, Stemi 1000), little device (A.Heiss) of cutting, microtome (SHANDON, Varistain 24-4Automatic Slide, U.K.) and the miniature thermometer probe of rectum (Harvard Homeothermic BlanketControl Unit).
4. method
Cerebral ischaemia, the cerebral arteries closure (MCAO) of central authorities
Via the permanent cerebral ischaemia that the cerebral arteries closure (MCAO) of central authorities causes, be under the situation of utilizing chloral hydrate (500 milligrams/10 milliliters of/kilogram IP) anesthesia, to carry out.The hair in temporal bone and parietal bone zone is shaved and is removed, and between the lateral surface of eye socket and the outside auditory meatus otch of incision of skin.Because temporalis muscle partly is cut open at its head apodeum, cause the upper end upset of parotid gland body of gland downward.See through translucent skull this moment and can see that central authorities are arteriocerebral long-range.
Amplify under the assistance of 10 times of stereoscopic microscopes one, utilize tooth section borer craniectomize, enlarge with meticulous synovectomy bone forceps then.Central authorities' cerebral arteries is cut off with little device of cutting by the ramose base portion of internal carotid artery place, then the temporalis muscle and the parotid gland is taken back.Otch after spilling some health mycins is sewed up scalp, and with 10% ketone iodine liquid (povidone iodinesolution) partly sterilised.At intra-operative, animal is by keeping normal body temperature by the equality of temperature heating system of being furnished with the little alternating temperature degree of rectum probe.With this understanding, the body temperature of rectum maintains in the physiological limits (37.5 ± 1.0 ℃).Performed the operation back 1 hour in, animal remains in the infant incubator (37.5 ± 1.0 ℃), to recover from anesthesia.After recovering, per 5 white mice are housed in the cage that can freely ingest and drink water, and remain in the clean Animal House (23.0 ± 10 ℃).
BNG-1 is dissolved in as in vectorial saline solution, be made into 10 milliliters/kilogram, control gets started continuous 7 days oral (PO) with the dosage of 1000 milligrams/kilogram (n=5) after MCAO, vehicle-control group (n=5) processing mode is identical, but only takes saline solution.Positive reaction control with the saline solution dissolving, is made into 5 milliliters/kilogram with reference to medicament MK-801 (RBI, Natick, MA 01760-2447, the U.S.), after MCAO 0,6,24,30,48 and 54 hours, carry out peritoneal injection with 0.3 milligram/kilogram dosage.
After ischemia injury the 8th day, all animals are all with the decapitation sacrifice.Their brain promptly is removed, and (NUAIRTM freezes in NU-6511) in the cryotherapy storehouse that is engraved in-70 ℃ of existing side by side.After the twenty four hours, with microtome (" SHANDON " Varistain 24-4Automatic Slide) the preparation crown section of complete brain (30 microns).Histological examination is carried out in each the 13rd section of selecting intactly to comprise 12 millimeters length plug region (as 390 microns parts).2% cresyl violet stains is used in whole 30 sections, to measure the damaged area of ischemia.This part is undertaken quantitatively by the image analysis instrument.Total ischemic region (mm of each crown section that calculating comes from each animal
2) and represent with meansigma methods ± SEM.Total thromboembolism volume (mm of each experimental group
3) with mm
2* length-specific (390 microns) calculates and represents with meansigma methods ± SEM.The treatment effect of BNG-1 and MK-801 is for using non-paired Xue Shengshi t value test method(s), and takes vectorial control group comparison, when * P＜0.05, is considered to the tool significant difference.Every animal all will be noted down body temperature in 0 minute (before the administration) and 30 minutes (after the administration).With the multiple no-load voltage ratio of Tukey than test method(s) relatively before the administration and the body temperature after the administration.
5. conclusion
The BNG-1 of 1000 milligrams/kilogram of continuous 7 days taking doses can effectively reduce the permanent cerebral ischaemia that (46.29%) white mice is caused because of central cerebral arteries closure behind the animal surgery.At continuous 7 days drug administration process, test animal did not have toxicity or mortality to take place.Body temperature does not obviously change yet.MK-801 obviously reduces (48.38%) cerebral ischaemia.
Embodiment 3:
As the step of example 2, male Sprange Dawely white mice is implemented central cerebral arteries Closure (MCAO), to cause nonvolatil cerebral ischaemia.
BNG-1 is dissolved in and is used as vectorial saline solution, before MCAO 7 days and 3 days afterwards, gives the oral dose (PO) of 1000 milligrams/kilogram of every days and 500 milligrams/kilogram respectively.Vehicle-control group is handled equally, but is only given saline solution.Positive reaction control with reference to medicament MK-801 after MCAO 0,6,24,30,48 and 54 hours, carry out peritoneal injection with 0.3 milligram/5 milliliters/kilogram dosage.
After ischemia injury the 4th day, all animals are all with the decapitation sacrifice.Total ischemic areas according to the identical step measurements It brain of example 2.
According to employed experiment condition, MCAO can be had an ischemia that causes the brain hemisphere 50%-60% that influenced of repeatability.By and large, the damaged area mostly concentrates on different cortex zone (for example, the cortex of forehead, sensation and motion, audition and occipital bone), and only is confined to the injury to neuroganglion base portion composition.With respect to vehicle-processing controls group, the dosage 0.3 milligram of/kilogram IP * 6, MK-801 reduce total thromboembolism volume 66.30 ± 10.50% significantly.Dosage 1000 milligrams of/kilogram PO * 10, BNG-1 reduce 44.09 ± 9.01% of thromboembolism volume significantly, and 500 milligrams/kilogram * 10 dosage reduce thromboembolism volume 14.17 ± 19.43% only not obviously.There is not chemical compound can cause that health body temperature significantly changes.
The safety pharmacological tests of BNG-1 is as follows:
Safety pharmacological testing (Safety Pharmacology
)
| Experimental project | Route of administration | Dosage or concentration | Active |
| White mice behavior reaction-Irwin screens (general behavior, the autonomic nerve conduction, 38 experiments such as nerve conduction and 7 days toxicity mortality rates are observed) | Oral | 0.5,1.0 and 2.0 (g/kilogram) | No influence |
| Central nervous system's (spontaneous activity sports coordination; prolongation during sleep; the protection of electric shock spasm; the reaction of Anticonvulsants; the inductive death of pentylenetetrazole-, tail spring reaction and phenylquinone-induce the body temperature variation of analgesic activity such as distortion and rat) | Oral | 0.5,1.0 and 2.0 (g/kilogram) | No influence |
| Respiratory circulatory system (the mean blood pressure of Canis familiaris L., the change of systolic pressure and diastolic pressure, the femoral artery rate of blood flow, heart rate, QT at interval, the PR interval, electrocardiogram variable and breathing rates such as QRS interval and S-T internode) | Oral | 1 (g/kilogram) | No influence |
| Renal excretion system (the urine amount of rat is discharged, the PH value of electrolyte excretion and urine) | Oral | 1 (g/kilogram) | No influence |
| Gastronintestinal system (gastrointestinal peristalsis of white mice) | Oral | 1 (g/kilogram) | No influence |
| The guinea pig ileum is to the contraction of (ethylene gallbladder ammonium is organized ammonium and barium chloride) | Outside exsomatizing | 1 (mg/ml) | Reduce and shrink |
| The guinea pig ileum shrinks ethylene gallbladder ammonium | Outside exsomatizing | (0.3 mg/ml) | Reduce and shrink |
Show by the result, 1 g/kilogram BNG-1 is given in the oral throwing of rat, should not have the misgivings of safety.
The acute toxic test of BNG-1
The dense thick suspension of BNG-1 of hero, female each six rat single dose (5 g/kilogram) is given in oral throwing, and matched group is thrown and given the contrast solution (1%CMC solution) that does not contain substances, measures the acute toxicity of BNG-1 to rat.After every rat gives the BNG-1 or contrast solution of twice (2 hours at interval) respectively, carry out the clinical observation fortnight.The result shows that rat does not all have any clinical toxicity symptom and manifests, and after dissecting rat, with macroscopy organ, tissue, does not also observe any pathological changes.Hence one can see that, and BNG-1 does not cause any observable acute toxicity of rat under the dosage of 5 g of per kilograms.Therefore, 5 g of per kilograms can be used as " dosage that does not have any impact " of BNG-1 (No observable effect level NOEL), and can classify as the material of " actual avirulence " (practically nontoxic).
Comprehensive above-mentioned result of the test shows that BNG-1 has prevention and the moving guanidine blocking function of treatment brain to white mice under the dosage of 1 g of per kilogram; And under this dosage, should not have the misgivings of safety, and do not have an acute toxicity.This result proves that BNG-1 blocks prevention to the moving guanidine of human brain and treatment has potentiality.
Also find simultaneously that BNG-1 has 67% lax activity to the lax idiopathic tension force of guinea pig trachea via the external administration approach that exsomatizes under 1 mg/ml dosage, and guinea pig is had 31% enhanced activity at atrium forward contractility.
Though the present invention is with reference to certain specific embodiments and on being described in, however the details of the present invention shown in being not limited to.In the claim of this case, still can make the many modifications that do not depart from spirit of the present invention.
Claims (3)
1. a Chinese medicine pharmaceutical compositions for the treatment of cerebral arteries emphraxis is made up of following eight kinds of Chinese crude drugs: Radix Ginseng, Radix Angelicae Sinensis, the Radix Astragali, Radix Glycyrrhizae, Radix Bupleuri, Rhizoma Coptidis, Concretio silicea Bambusae seu schizostachyi and Radix Scutellariae basically;
Wherein the weight ratio of the Chinese crude drug of this pharmaceutical compositions is a Radix Ginseng: Radix Angelicae Sinensis: the Radix Astragali: Radix Glycyrrhizae: Radix Bupleuri: Rhizoma Coptidis: Concretio silicea Bambusae seu schizostachyi: Radix Scutellariae=140 ± 10%: 166 ± 10%: 180 ± 10%: 67 ± 10%: 140 ± 10%: 120 ± 10%: 120 ± 10%: 67 ± 10%.
2. pharmaceutical compositions as claimed in claim 1, wherein these eight kinds of Chinese crude drugs are dried powder.
3. one kind is used following eight kinds of Chinese crude drugs to prepare to be used for the treatment of and the method for the medicine of prevention of brain obstruction of artery, and these eight kinds of Chinese crude drugs are Radix Ginseng, Radix Angelicae Sinensis, the Radix Astragali, Radix Glycyrrhizae, Radix Bupleuri, Rhizoma Coptidis, Concretio silicea Bambusae seu schizostachyi and Radix Scutellariae; This medicine be with these eight kinds of Chinese crude drugs through infusion, cure, dry and grind after formed powder;
Wherein the weight ratio of these eight kinds of Chinese crude drugs is a Radix Ginseng: Radix Angelicae Sinensis: the Radix Astragali: Radix Glycyrrhizae: Radix Bupleuri: Rhizoma Coptidis: Concretio silicea Bambusae seu schizostachyi: Radix Scutellariae=140 ± 10%: 166 ± 10%: 180 ± 10%: 67 ± 10%: 140 ± 10%: 120 ± 10%: 120 ± 10%: 67 ± 10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011367709A CN1309409C (en) | 2001-10-25 | 2001-10-25 | Chinese medicine composite for treatment and prevention of cerebral arteries obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011367709A CN1309409C (en) | 2001-10-25 | 2001-10-25 | Chinese medicine composite for treatment and prevention of cerebral arteries obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1413609A CN1413609A (en) | 2003-04-30 |
| CN1309409C true CN1309409C (en) | 2007-04-11 |
Family
ID=4673900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011367709A Expired - Fee Related CN1309409C (en) | 2001-10-25 | 2001-10-25 | Chinese medicine composite for treatment and prevention of cerebral arteries obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1309409C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053189A (en) * | 1990-12-25 | 1991-07-24 | 冯虎平 | The preparation method of " promoting blood circulation and restoring paralysis pills " |
-
2001
- 2001-10-25 CN CNB011367709A patent/CN1309409C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053189A (en) * | 1990-12-25 | 1991-07-24 | 冯虎平 | The preparation method of " promoting blood circulation and restoring paralysis pills " |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1413609A (en) | 2003-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN116098964B (en) | Traditional Chinese medicine composition for treating thyroid nodule and preparation and application thereof | |
| CN102145120A (en) | Traditional Chinese medicine composition suitable for treating Type II diabetes | |
| CN1309409C (en) | Chinese medicine composite for treatment and prevention of cerebral arteries obstruction | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN104587267A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN1326547C (en) | Chinese medicine composition for treating coronary heart disease and its prepn | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| EP1358887B1 (en) | Composition of traditional chinese medicines for preventing and treating cerebrovascular disease | |
| US6872409B2 (en) | Composition of traditional chinese medicines for preventing and treating cerebrovascular disease | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| KR100502947B1 (en) | Composition of traditional chinese medicines for preventing and treating cerebrovascular disease | |
| CN112294901B (en) | Traditional Chinese medicine composition for treating supraventricular arrhythmia and preparation method and application thereof | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN104435657B (en) | A kind of medicine for preventing and treating prostate cancer endocrine therapy side effect and preparation method thereof | |
| CN112891416B (en) | A Chinese medicinal composition for treating psoriasis | |
| CN100551404C (en) | Medicament for inducing diuresis to alleviate edema preparation of compositions and detection method and purposes | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN104940730A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN101391052A (en) | Traditional Chinese medicine composition for treating cerebral arteries emphraxis | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070411 Termination date: 20191025 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |